Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

U.S. to retry Senator Menendez on bribery, corruption charges

Published 01/19/2018, 04:26 PM
Updated 01/19/2018, 04:26 PM
© Reuters. U.S. Senator Menendez speaks to media as he departs the United States Court in Newark

By Joseph Ax

NEW YORK (Reuters) - The U.S. Justice Department said on Friday it plans to retry Democratic U.S. Senator Robert Menendez on bribery and corruption charges after a jury was deadlocked during a trial in November.

The government is seeking the "earliest possible date" for a retrial, according to a court filing. Menendez, who has represented New Jersey in the Senate since 2006, is expected to run for another six-year term this year, and the state's Democratic leaders have endorsed his bid despite the charges.

"The decision to retry this case was made based on the facts and the law, following a careful review," the Justice Department said in a statement.

Menendez, 64, is accused of accepting private flights, campaign contributions and other bribes from a wealthy patron, Florida ophthalmologist Salomon Melgen, in exchange for official favors.

Melgen, who was separately convicted last year in Florida of perpetrating a massive Medicare fraud, will also be retried, the Justice Department said.

"We regret that the DOJ, after spending millions and millions of taxpayer dollars, and failing to prove a single allegation in a court of law, has decided to double down on an unjust prosecution," Menendez's office said in a statement. "Evidently, they did not hear the overwhelming voices of the New Jerseyans who served on the jury this fall. Senator Menendez fully intends to be vindicated - again."

A lawyer for Melgen, Kirk Ogrosky, said in an email that they were "disappointed" in the decision to continue a "ridiculous" prosecution.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The case was the first high-profile corruption trial for federal prosecutors since a U.S. Supreme Court decision in 2016 limited their ability to bring such charges.

A second trial this year could pose a major distraction for Menendez and his fellow Democrats, who are already facing an unfriendly electoral map in their quest to wrest control of the Senate.

Republicans hold a narrow 51-49 advantage but only have to defend eight seats, compared with 26 for Democrats and independents who caucus with them.

During the 10-week trial last year, prosecutors said Melgen showered Menendez with gifts. In exchange, they said, Menendez pressured Medicare officials to revamp the agency's billing policies after Melgen was found to have overbilled it by millions of dollars.

The senator also helped secure visas for Melgen's foreign girlfriends and asked U.S. officials to resolve a port dispute in the Dominican Republic involving one of Melgen's companies, prosecutors said.

Defense attorneys said Menendez and Melgen were simply close friends.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.